Addiction, Author Interviews, Opiods, PLoS / 04.02.2022

MedicalResearch.com Interview with: Dr. Laurence Moss MD, PhD candidate Centre for Human Drug Research (CHDR) Department of Anesthesiology Leiden University Medical Centre (LUMC) Geert Jan Groeneveld​, MD, PhD Neurologist | Clinical Pharmacologist | Professor of Clinical Neuropharmacology CMO/CSO Centre for Human Drug Research Leiden, The Netherlands  MedicalResearch.com:  What is the background for this study?    Response: Opioid use disorder (OUD) is a major source of morbidity and mortality, and the opioid epidemic in the Unites States (but increasingly in Europe also) has been well documented and reported on by the media. The alarming rise in opioid related mortality is largely driven by the increasing use of fentanyl and fentanyl analogues, often surreptitiously mixed with heroin or other drugs such as psychostimulants or prescribed opioids. Opioid-induced respiratory depression in particular is a leading cause of opioid-related fatalities. Buprenorphine has been proven as an effective medication for the treatment of OUD. Buprenorphine is a semi-synthetic partial agonist for the opioid receptor that firmly binds to these receptors and displays only partial respiratory depressive effects, meaning it does not cause the complete cessation of breathing as is the case with other potent opioids such as fentanyl. Due to its firm receptor binding, we hypothesized that at sufficient buprenorphine receptor occupancy, the effect of fentanyl on respiration would be limited, even at high fentanyl doses. This study aimed to provide proof of principle for this hypothesis, and demonstrate whether buprenorphine could reduce fentanyl-induced respiratory depression.
Author Interviews, COVID -19 Coronavirus, JAMA, NYU/NYMC / 03.02.2022

MedicalResearch.com Interview with: [caption id="attachment_58722" align="alignleft" width="150"]Andrea B. Troxel, ScD (she/her/hers) Professor and Director, Division of Biostatistics Department of Population Health NYU Grossman School of Medicine NYU Langone Health Dr. Troxel[/caption] Andrea B. Troxel, ScD (she/her/hers) Professor and Director, Division of Biostatistics Department of Population Health NYU Grossman School of Medicine NYU Langone Health MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: This study represents an international collaboration across four continents and six countries, to pool information from studies in different patient populations to generate robust information about the possible benefits of convalescent plasma in treating COVID-19. Because the study was so large and the methods so rigorous, we were able to show that while CP doesn’t benefit all patients, it may have positive effects in certain subgroups.
AHA Journals, Author Interviews, Blood Pressure - Hypertension, Race/Ethnic Diversity, Social Issues / 03.02.2022

MedicalResearch.com Interview with: Xing Gao, MPH, lead author and doctoral candidate in Dr. Mujahid's research group Mahasin Mujahid, MS, PhD, FAHA Lillian E. I. and Dudley J. Aldous Chair in the School of Public Health Associate Professor of Epidemiology Director, Epidemiology & Biostatistics Master of Public Health Program UC Berkeley, School of Public Health MedicalResearch.com:  What is the background for this study?  What are the main findings?
  • ​​Hypertension is a major risk factor for cardiovascular diseases, and persistent racial and ethnic inequities in hypertension remain an urgent public health challenge.
  • Public health researchers need a more nuanced understanding of how structural factors contribute to these inequities, which has a direct application to improving the cardiovascular health of marginalized populations.
  • This study examined associations between racial residential segregation, a product of historical and contemporary racially discriminatory policies, and hypertension in a multi-racial cohort of middle-aged and older adults. 
Author Interviews, COVID -19 Coronavirus, Technology / 03.02.2022

MedicalResearch.com Interview with: [caption id="attachment_58711" align="alignleft" width="150"]Michael J. Mahan Ph.D Professor Dept of Molecular, Cellular, and Developmental Biology University of California, Santa Barbara, CA 93106-9625 Dr. Mahan[/caption] Michael J. Mahan Ph.D Professor Dept of Molecular, Cellular, and Developmental Biology University of California, Santa Barbara, CA 93106-9625 MedicalResearch.com:  What is the background for this study?  Response: A critical need exists in resource-poor settings for low-cost, low-tech, yet highly reliable and scalable testing for SARS-CoV-2 virus that is robust against circulating variants. 
Author Interviews, COVID -19 Coronavirus, JAMA, Pediatrics, Respiratory, Yale / 03.02.2022

MedicalResearch.com Interview with: [caption id="attachment_58724" align="alignleft" width="200"]Thomas Murray MD PhD Associate Professor, Yale School of Medicine Department of Pediatrics, Infectious Disease and Global Health Associate Medical Director, Infection Prevention Yale New Haven Children's Hospital Dr. Murray[/caption] Thomas Murray MD PhD Associate Professor, Yale School of Medicine Department of Pediatrics, Infectious Disease and Global Health Associate Medical Director, Infection Prevention Yale New Haven Children's Hospital MedicalResearch.com:  What is the background for this study?  Response: This study was performed by Yale- CARES (Children and Adults Research in Early Education Study Team) a multidisciplinary group of researchers that are interested in learning how the COVID-19 pandemic has impacted early child care programs in the US including the effects on both the children and those who care for them in this setting. This is important because when child care programs close it becomes very difficult for working families to find safe, affordable alternative care. We surveyed over 6000 child care workers from across the US in May/June 2020 with a follow up survey in May/June 2021. This includes both center based and home based child care programs. One question we were interested in was what things they were doing in their programs to reduce the risk of COVID-19. We then asked whether their program closed at any time in that year because of COVID-19.
AHA Journals, Author Interviews, Heart Disease, Social Issues, UCSD / 03.02.2022

[caption id="attachment_58733" align="alignleft" width="150"]Natalie Golaszewski, PhD Herbert Wertheim School of Public Health and Human Longevity Science University of California, San Diego  La Jolla, CA 92093 Dr. Golaszewski[/caption] MedicalResearch.com Interview with: Natalie Golaszewski, PhD Herbert Wertheim School of Public Health and Human Longevity Science University of California, San Diego La Jolla, CA 92093 MedicalResearch.com:  What is the background for this study?  Response: Social isolation and loneliness are growing public health concerns as they are associated with health conditions that increase the risk of cardiovascular disease including obesity, smoking, physical inactivity, poor diet, high blood pressure and high cholesterol.
Author Interviews, Heart Disease, JAMA, NYU/NYMC, USPSTF / 02.02.2022

MedicalResearch.com Interview with: [caption id="attachment_56129" align="alignleft" width="133"]Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine Dr. Ogedegbe[/caption] Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine Member of the U.S. Preventive Services Task Force MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: Atrial Fibrillation (AFib) is the most common type of irregular heartbeat and a major risk factor for stroke, and it often goes undetected. For this recommendation, the Task Force evaluated whether screening adults over the age of 50 who do not have any signs or symptoms of AFib can help prevent strokes. In its evidence review, Task Force expanded its scope to include a search for studies on portable and wearable devices such as smartphones and fitness trackers in addition to electrocardiography (ECG). Despite this consideration, the Task Force found insufficient evidence to recommend for or against screening for AFib. This is consistent with the Task Force’s 2018 recommendation.
Author Interviews, COVID -19 Coronavirus, JAMA / 28.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58730" align="alignleft" width="200"]Eva Petkova, PhD  Professor, NYU School of Medicine Department of Population Health Division of Biostatistics Department of Child and Adolescent Psychiatry New York, NY 10016 Senior Scientist, Nathan Kline Institute of Psychiatric Research Orangeburg, NY 10962 Dr. Petkova[/caption] Eva Petkova, PhD Professor, NYU School of Medicine Department of Population Health Division of Biostatistics Department of Child and Adolescent Psychiatry, New York, NY 10016 Senior Scientist, Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962 MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: The COMPILE study is based on real-time collection of individual patient data from 8 international completed, terminated early and ongoing randomized clinical trials testing the efficacy of convalescent plasma for the treatment of hospitalized patients with COVID-19. Recruitment covered the period from March 2020 to March 2021 in Asia, Europe, North and South America. Total of 2369 patients were enrolled and data from 2341 patients were used in the analysis. COMPILE, the largest study of convalescent plasma for hospitalized COVID-19 patients to date, provided robust information on a diverse patient population, which allowed rigorous evaluation of questions related to convalescent plasma efficacy. The main findings are that convalescent plasma might have only a moderate efficacy on average, but that there is a huge heterogeneity in the benefits for individual patients.
Author Interviews, Dermatology, Emory, JAMA, Race/Ethnic Diversity / 27.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58708" align="alignleft" width="150"]Howa Yeung, MD MSc | He/him/his Assistant Professor of Dermatology Emory University School of Medicine Atlanta, GA 30322 Dr. Yeung[/caption] Howa Yeung, MD MSc | He/him/his Assistant Professor of Dermatology Emory University School of Medicine Atlanta, GA 30322 MedicalResearch.com:  What is the background for this study?  Response: Asian Americans are the fastest growing racial group in the United States but are underrepresented in health research. Existing research often categorize Asian Americans into a single racial category, which may mask differences in health behaviors and outcomes subgroups. We sought to examine potential differences in skin cancer-related risk factors and screening among Asian Americans in a large, nationally representative study.
Author Interviews, COVID -19 Coronavirus, JAMA, Race/Ethnic Diversity / 26.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58692" align="alignleft" width="200"]Tasleem J. Padamsee, PhD Co-Leader  C3-REACH -- Committed to Communities Collaborative: Research and Engagement to Advance beyond COVID to Health EquityPrincipal Investigator The Daughter Sister Mother Project: Empowering Women and their Healthcare Providers to Fight Familial Cancer Lead Qualitative Investigator WOW Project: Washington & Ohio Workers Study Assistant Professor Division of Health Services Management & Policy, College of Public Health Faculty Affiliate, James Comprehensive Cancer Center The Ohio State University Dr. Padamsee[/caption] Tasleem J. Padamsee, PhD Co-Leader  C3-REACH -- Committed to Communities Collaborative: Research and Engagement to Advance beyond COVID to Health EquityPrincipal Investigator The Daughter Sister Mother Project: Empowering Women and their Healthcare Providers to Fight Familial Cancer Lead Qualitative Investigator WOW Project: Washington & Ohio Workers Study Assistant Professor Division of Health Services Management & Policy, College of Public Health Faculty Affiliate, James Comprehensive Cancer Center The Ohio State University MedicalResearch.com:  What is the background for this study?  Response: This is a study about COVID-19 vaccine hesitancy in the United States. Although there has been a lot of discussion about vaccine hesitancy as a barrier to achieving high rates of COVID-19 vaccination, there have been few studies of changes in hesitancy - or how it might vary across groups. As COVID-19 vaccines were becoming available in the US there was a lot of discussion about worrisome rates of vaccine hesitancy, particularly among communities of color. Our team suspected, however, that these high rates might be short-lived, and that Black Americans in particular might become willing to use COVID-19 vaccines after a short period of time - as they became reassured that they would be safe, effective, and protect communities.
Author Interviews, CDC, COVID -19 Coronavirus, Emory, Heart Disease, JAMA / 25.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58700" align="alignleft" width="200"] Dr. Oster[/caption] Matthew Oster, MD, MPH CDC COVID-19 Response CDC Center on Birth Defects and Developmental Disabilities Pediatric Cardiologist, Sibley Heart Center, Children’s Healthcare of Atlanta Emory University School of Medicine Emory University Rollins School of Public Health MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: More than 192 million people ages 12 years and older in the U.S. received at least one dose of mRNA COVID-19 vaccines from December 2020 through August 2021. From this population, VAERS (the Vaccine Adverse Event Reporting System) received 1,991 reports of myocarditis,  1,626 of which met the case definition of myocarditis. Rates of myocarditis were highest following the second dose of an mRNA vaccine among males aged 12–15 years (70.7 per million doses of Pfizer), 16-17 years (105.9 per million doses of Pfizer), and 18–47 years (52.4 and 56.3 per million doses of Pfizer and Moderna, respectively). Of those with myocarditis, the median age was 21 years and the median time from vaccination to symptom onset was two days. Males accounted for 82% of patients for whom sex was known. Approximately 96% were hospitalized, 87% of whose symptoms had gone away by the time they were discharged from the hospital. Non-steroidal anti-inflammatory drugs (589/676, 87%) were the most common treatment.
Author Interviews, Kidney Disease, Rheumatology / 24.01.2022

[caption id="attachment_58695" align="alignleft" width="150"]Stephen Connelly, PhD, Chief Scientific Officer, Equillium Dr. Connelly[/caption] Stephen Connelly, PhD Co-founder & Chief Scientific Officer Equillium, Inc. San Diego, California MedicalResearch.com:  What is the background for this study?    Response: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that predominantly affects women in the reproductive age range. Approximately 50% of SLE patients experience lupus nephritis (LN), a serious complication that is accompanied by significant morbidity and mortality. Progression of LN to chronic kidney disease is common, with 10% of patients with LN developing end-stage kidney disease. T cells, play a central role in the pathogenesis of both SLE and LN by mediating tissue damage and enhancing the production of autoantibodies by promoting B cell differentiation, proliferation, and maturation. These T cells express CD6, a costimulatory receptor that through its binding to activated leukocyte cell adhesion molecule (ALCAM), expressed on immune cells and tissues, modulates both the activity and trafficking of effector T cells (Teff). The expression of both CD6 and ALCAM (CD6-ALCAM pathway) have been associated with pathogenic effector T cell activity and trafficking in multiple autoimmune and inflammatory diseases. Based on a comprehensive screen of more than 1100 urine proteins, soluble urinary ALCAM (uALCAM) was identified as one of only a few molecules that were elevated in the urine of patients with SLE with active renal involvement compared with patients with quiescent or no prior nephritis. However, no studies had been conducted to characterize the cellular sources of the soluble ALCAM and questions remained about the relevance of this protein and whether it was associated with the pathology of the disease.
Aging, Author Interviews, Dental Research, Geriatrics, NYU/NYMC / 23.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58688" align="alignleft" width="200"]Bei Wu, PhD Dean's Professor in Global Health Vice Dean for Research Rory Meyers College of Nursing Affiliated Professor, College of Dentistry Co-Director, NYU Aging Incubator New York University New York, NY 10010 Dr. Bei Wu[/caption] Bei Wu, PhD Dean's Professor in Global Health Vice Dean for Research Rory Meyers College of Nursing Affiliated Professor, College of Dentistry Co-Director, NYU Aging Incubator New York University New York, NY 10010 MedicalResearch.com:  What is the background for this study?    Response: Social isolation and loneliness are global public health concerns. Social isolation is the lack of social contacts and having few people to have regular interactions; while loneliness is the distressing feeling of being alone or separated. Approximately 24% of community-dwelling older adults aged 65 and above are considered to be socially isolated in the United States, and 43% adults aged over 60 years old report feeling lonely. Increasing evidence suggests that social isolation and loneliness are risk factors for older adults’ health outcomes, such as depression, comorbidities, cognitive impairment and dementia, and premature mortality. However, one key limitation in the literature is that only a few studies have examined the impact of social isolation and loneliness on oral health.
Author Interviews, BMJ, Orthopedics / 20.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58670" align="alignleft" width="150"]Prof. Matthew Costa Professor of Orthopaedic Trauma University of Oxford Honorary Consultant Trauma Surgeon, John Radcliffe Hospital, Oxford Prof. Costa[/caption] Prof. Matthew Costa Professor of Orthopaedic Trauma University of Oxford Honorary Consultant Trauma Surgeon, John Radcliffe Hospital, Oxford  MedicalResearch.com: What is the background for this study? Response: Fixation with metal implants provides reliable functional outcomes for patients after a manipulation of a displaced fracture of the distal radius, but such surgery carries risk for the patient and is expensive. A moulded plaster cast is a safer and cheaper intervention but may not provide the same functional outcome. It is not known which of these treatments is superior.
Author Interviews, Diabetes, NEJM, Pediatrics, Technology / 20.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58667" align="alignleft" width="200"]Dr Julia Ware (née Fuchs) Clinical Research Associate Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories  and Medical Research Council Metabolic Diseases Unit, University of Cambridge Addenbrooke’s Hospital, Cambridge  Dr. Ware[/caption] Dr Julia Ware (née Fuchs) Clinical Research Associate Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, University of Cambridge Addenbrooke’s Hospital, Cambridge MedicalResearch.com: What is the background for this study? Response: Management of type 1 diabetes is challenging in very young children, due to their high variability of insulin requirements and unpredictable eating and activity patterns. As a result, many young children do not meet the recommended glycemic targets, or only maintain recommended glycemic control with extensive caregiver input. This in turn leads to high management burden and reduced quality of life for the whole family. While the increasing use of continuous glucose-monitoring devices and insulin-pump therapy has led to reductions in the incidence of severe hypoglycaemia and diabetic ketoacidosis, and has been accompanied by modest improvements in glycemic control, the burden of management has remained high. Hybrid closed-loop systems (also called an artificial pancreas), in which an algorithm automatically adjusts insulin delivery on the basis of real-time sensor glucose levels, may address ongoing challenges in this age group. However, to date hybrid closed-loop studies involving very young children have been small and of short duration and the efficacy and safety of longer term use of a closed-loop system, as compared with standard therapy, was unclear.   To address this knowledge gap, we compared 16-week use of the Cambridge closed-loop algorithm with sensor-augmented pump therapy in children aged 1 to 7 years with type 1 diabetes in a multi-national randomised crossover study.
Author Interviews, Ophthalmology, PLoS / 20.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58681" align="alignleft" width="263"]Jugnoo S Rahi  Professor of Ophthalmic Epidemiology and Honorary Consultant Ophthalmologist NIHR Senior Investigator Prof. Rahi[/caption] Prof. Jugnoo S Rahi Professor of Ophthalmic Epidemiology and Honorary Consultant Ophthalmologist NIHR Senior Investigator Head, Vision and Eyes Group UCL Head, Population Policy and Practice Research and Teaching Department GOS ICH UCL Director, Ulverscroft Vision Research Group  GOS Institute of Child Health UCL / Great Ormond Street Hospital NHS Foundation Trust Institute of Ophthalmology UCL / NIHR Moorfields Biomedical Research Centre Chair, Academic Committee Chair, British Ophthalmological Surveillance Unit Executive Committee Royal College of Ophthalmologists  MedicalResearch.com:  What is the background for this study?    Response: We hypothesised that if changing environmental factors, in particular educational experience, are accounting for increasing frequency of myopia in the UK, a cohort effect would be discernible in changing associations with myopia, with different profiles for childhood and adult-onset forms. We investigated this using the UK Biobank Study, a unique large contemporary adult population sample whose members, born over a period of more than three decades, have undergone a detailed ophthalmic examination. This affords the opportunity to analyse ‘historical’ cohorts covering a period of important socio-demographic, economic, and educational change in the UK from which current and emerging trends may be identified and examined. Drawing on our previous proof-of-concept study, we investigated whether there were differences between childhood-onset versus adult-onset myopia in temporal trends in both frequency and severity and in associations with key environmental factors.
Author Interviews, Multiple Sclerosis / 19.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58674" align="alignleft" width="150"]Marcus Koch Dr. Koch[/caption] Marcus Koch MD PhD Associate Professor of Neurology Multiple Sclerosis Program University of Calgary MedicalResearch.com: What is the background for this study? Response: Primary progressive multiple sclerosis (PPMS) is the least common, but also the least treatable form of multiple sclerosis. PPMS does not react well to commonly used MS treatments. We believe that this is at least in part because PPMS is driven by other disease mechanisms. One disease mechanism that we believe is important in PPMS is microglial activation. Microglial cells are a type of cell in the brain and spinal cord that normally have beneficial functions, such as clearing debris or assisting repair after injury. In PPMS however, microglial cells are chronically active, and we believe that this chronic microglial activation contributes to tissue damage.
Author Interviews, Critical Care - Intensive Care - ICUs, JAMA, Pediatrics / 18.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58650" align="alignleft" width="150"]Edward Bell, MD Professor of Pediatrics-Neonatology Vice Chair for Faculty Development, Stead Family Department of Pediatrics Roy J. and Lucille A. Carver College of Medicine University of Iowa Dr. Bell[/caption] Edward Bell, MD Professor of Pediatrics-Neonatology Vice Chair for Faculty Development, Stead Family Department of Pediatrics Roy J. and Lucille A. Carver College of Medicine University of Iowa MedicalResearch.com: What is the background for this study? Response: The National Institute of Child Health and Human Development, a branch of the National Institutes of Health (NIH), has supported the Neonatal Research Network (NRN) since 1986. The NRN, a group of US academic centers, is tasked with conducting research to improve the treatment and health outcomes of premature and critically-ill babies in US neonatal intensive care units (NICUs). Every few years, the NRN publishes reports on the survival rates and outcomes of surviving extremely premature babies, those born before 28 weeks of gestation. These reports help us to judge progress in the care and outcomes of these infants. This paper is the 9th in this series of reports but the first that includes not only survival and in-hospital outcomes but also outcomes at 2 years of age. 
Author Interviews, Duke, Gastrointestinal Disease, Nature, Sugar / 17.01.2022

MedicalResearch.com Interview with: Laura Rupprecht, PhD Postdoctoral Fellow Kelly L Buchanan The Laboratory of Gut Brain Neurobiology Duke Medicine – GI Diego V. Bohórquez PhD Associate Professor in Medicine Duke Institute for Brain Sciences Durham, NC MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: In 2018, my laboratory discovered that a cell type in the gut epithelium synapses with the vagus nerve, the nerve which connects the gut and the brain. These gut cells are called neuropod cells. Neuropod cells transduce sugar within milliseconds using the neurotransmitter glutamate. Since then, we have been interested in defining how this rapid communication between neuropod cells and the brain regulates behavior. – Diego Bohórquez Over a decade ago, it was shown that the gut is the key site for discerning sugar and non-caloric sweetener. But the specific cell in the gut that underlies this effect was unknown. – Kelly Buchanan  
Author Interviews, Brigham & Women's - Harvard, Infections, Multiple Sclerosis, Science / 15.01.2022

MedicalResearch.com Interview with: Kassandra L. Munger Sc.D. Senior Research Scientist Alberto Ascherio MD Dr.P.H. Professor of Epidemiology and Nutrition Harvard T.H. Chan School of Public Health MedicalResearch.com: What is the background for this study? Response: An infectious cause of MS has been hypothesized for decades. Research over the past 20 years conducted by our group and others has strongly suggested a role for EBV infection including that EBV-negative individuals have a near zero risk of developing MS, having a history of infectious mononucleosis (caused by EBV infection) increases the risk of MS 2-fold, and healthy individuals have higher risks of MS with higher antibody levels against EBV antigens.  Ideally, to prove causality a randomized clinical controlled trial would be conducted; however, this not a feasible approach in this case. Given that nearly 95% of the adult population is infected with EBV and MS is a rare disease, we utilized the Department of Defense Serum Repository which stores over 60 million serum samples from over 10 million US Military active duty personnel. From this large resource, we were able to identify a cohort who were EBV negative when they joined the military and we followed them for whether they had a primary infection with EBV and then for who developed MS.
Author Interviews, Kidney Disease, Race/Ethnic Diversity / 13.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58647" align="alignleft" width="200"]Joshua D. Bundy, PhD, MPH Department of Epidemiology Tulane University School of Public Health and Tropical Medicine and Tulane University Translational Science Institute New Orleans Louisiana Dr. Bundy[/caption] Joshua D. Bundy, PhD, MPH Department of Epidemiology Tulane University School of Public Health and Tropical Medicine and Tulane University Translational Science Institute New Orleans Louisiana MedicalResearch.com: What is the background for this study? What is included in the KFRE score? Response: Kidney function is quantified using estimated glomerular filtration rate (eGFR), which is often calculated in clinical practice using filtration markers like serum creatinine and/or cystatin C, and patient characteristics like age, sex, and race. Recently, new eGFR equations were created that remove race adjustment because of concerns that using a patient’s race may perpetuate racial inequities in healthcare delivery. The Kidney Failure Risk Equation (KFRE) is the most commonly-used tool to predict end-stage kidney disease (ESKD) risk and includes age, sex, eGFR, and urinary albumin-creatinine ratio. We sought to evaluate the impact of removing race from eGFR on prediction of ESKD. 
Author Interviews, COVID -19 Coronavirus, Environmental Risks, Technology / 13.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58643" align="alignleft" width="150"]Krystal Pollitt, PhD, P.Eng. Dr. Pollitt[/caption] Krystal Pollitt, PhD, P.Eng. Assistant Professor of Epidemiology (Environmental Health Sciences) Assistant Professor in Chemical and Environmental Engineering Affiliated Faculty, Yale Institute for Global Health Yale School of Public Health  MedicalResearch.com: What is the background for this study? Response: People infected with COVID-19 can release SARS-CoV-2 virus in aerosol and droplets when they exhale. This can be from coughing or sneezing but also when they speaker or just breathe. While the larger droplets can settle to the ground quickly (seconds to minutes), smaller aerosol can remain in the air in longer periods (minutes to hours). SARS-CoV-2 can be transmitted by inhaling aerosol or droplets containing infectious virus. The Fresh Air Clip enables detection of droplet and aerosol containing virus.
Author Interviews, Diabetes, Global Health, Lancet / 12.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58638" align="alignleft" width="150"]Prof Dianna J Magliano PhD Baker Heart and Diabetes Institute Melbourne Australia Prof. Magliano[/caption] Prof Dianna J Magliano PhD Baker Heart and Diabetes Institute Melbourne Australia  MedicalResearch.com: What is the background for this study? Response: Mortality among people with diabetes, and how it changes over time, is an important indicator of quality of and access to health care. However, population level trends in mortality among people with diabetes are inadequately described. The establishment of national diabetes registers, health insurance data and administrative data has allowed the examination of mortality among those with diabetes at a granular level which has been previously not possible. This has allowed us to examine whether global efforts in regards to diabetes care over the last couple of decades have been effective.
Author Interviews, Environmental Risks, Gastrointestinal Disease / 11.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58634" align="alignleft" width="150"]Morgan Walker Ph.D. Candidate, UNC-Chapel Hill Chemistry Redinbo Laboratory Morgan Walker[/caption] Morgan Walker Ph.D. Candidate, UNC-Chapel Hill Chemistry Redinbo Laboratory MedicalResearch.com: What is the background for this study? Where is triclosan commonly found? Response: Triclosan is a commonly found antibacterial compound present in hand soaps, toothpastes, athletic clothes, and children’s toys. A previous study by the Zhang group (corresponding author on this publication) found that antimicrobial compounds including triclosan increased inflammation (similar to that of inflammatory bowel disease (IBD)) and tumor formation in the colon. These effects were observed only in mice with an intact gut microbiome, not in germ-free mice which lack a gut microbiome, suggesting that the gut microbiome is somehow responsible for the toxicity of triclosan to the gut. Our study investigates how gut bacteria promote triclosan toxicity in the gut 
Author Interviews, COVID -19 Coronavirus, JAMA, Pediatrics / 11.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58626" align="alignleft" width="150"]Stephen Freedman MDCM, MSc Professor of Pediatrics and Emergency Medicine Alberta Children’s Hospital Foundation Professor in Child Health and Wellness Alberta Children’s Hospital Research Institute, Cumming School of Medicine University of Calgary Dr. Freedman[/caption] Stephen Freedman MDCM, MSc Professor of Pediatrics and Emergency Medicine Alberta Children’s Hospital Foundation Professor in Child Health and Wellness Alberta Children’s Hospital Research Institute, Cumming School of Medicine University of Calgary MedicalResearch.com: What is the background for this study? Response: During the early stages of the global 2019 coronavirus disease (COVID-19) pandemic, children represented fewer than 5% of reported cases.  However, children now represent a significant percent of all new COVID-19 cases.  Similarly, pediatric hospitalizations due to COVID-19, are now at an all-time high.  Although COVID-19 is generally mild in children, severe outcomes and death do occur.  The risk of severe outcomes among SARS-CoV-2 infected children is poorly understood with estimates varying considerably between study designs, settings, and regions.  Studies generally include large administrative databases (i.e. community based), hospitalized populations, and children admitted to the intensive care unit (ICU). Identified risk factors for severe COVID-19 in children have included young (i.e. 1-3 months) or old (15-18 years) pediatric age group, male sex, and pre-existing medical condition.  However, data from large prospective cohort studies which include children with early or mild stages of disease seeking emergency department (ED) care are lacking. To address this knowledge gap we sought to quantify the frequency of and risk factors for severe outcomes in SARS-CoV-2 infected children enrolled in a prospective ED-based cohort study. 
ADHD, Author Interviews, Cost of Health Care, Eating Disorders, Pharmacology / 09.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58622" align="alignleft" width="125"]MedicalResearch.com Interview with: Sneha Vaddadi, BS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, Pennsylvania Sneha Vaddadi[/caption] Sneha Vaddadi, BS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, Pennsylvania MedicalResearch.com: What is the background for this study? Response: The prescription stimulants methylphenidate, amphetamine, and lisdexamfetamine, classified as Schedule II substances, are sympathomimetic drugs with therapeutic use widely used in the US for Attention Deficit Hyperactivity Disorder. Changes in criteria for diagnosis of Attention Deficit Hyperactivity Disorder in 2013 and approval of lisdexamfetamine for binge eating disorder in 2015 may have impacted usage patterns. The goal of this study1 was to extend upon past research2 to compare the pharmacoepidemiology of these stimulants in the United States from 2010–2017, including consideration to variation within geographic regions, the Hispanic population, and the Medicaid population.
Author Interviews, Cannabis, JAMA, Pediatrics / 07.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58615" align="alignleft" width="150"]Daniel Myran, MD, MPH, CCFP, FRCPC Family and Public Health and Preventive Medicine Physician  CIHR Fellow, Ottawa Hospital Research Institute  Department of Family Medicine Innovation Fellow University of Ottawa  Dr. Myran[/caption] Daniel Myran, MD, MPH, CCFP, FRCPC Family and Public Health and Preventive Medicine Physician CIHR Fellow, Ottawa Hospital Research Institute Department of Family Medicine Innovation Fellow University of Ottawa MedicalResearch.com: What is the background for this study? Response: Canada legalized recreational, or non-medical, cannabis in October 2018. Canada took phased approach to legalization initially only allowing flower-based cannabis products and oils and after one year permitting the sale of commercial cannabis edibles (e.g. THC containing candies, baked goods, and drinks). In this study we took advantage of this phased roll out of legal cannabis to understand the impact of legalization on cannabis exposures or poisonings in children aged 0-9 years and the contribution of different types of cannabis products to these events.
Author Interviews, Cancer Research, Nutrition, Supplements / 06.01.2022

MedicalResearch.com Interview with: Dr Rana Conway PhD RNutr  Research Fellow Energy Balance & Cancer Group, and Obesity Research Group Research Department of Behavioural Science and Health University College London    MedicalResearch.com: What is the background for this study? Response: We’ve seen great advances in cancer diagnosis and treatment in recent years which means the number of people living with and beyond a cancer diagnosis is rapidly increasing. The WCRF and CRUK recommend improving diet and exercise to reduce the risks of cancer coming back but we know anecdotally that supplements are sometimes seen as an easier option, and people who’ve had cancer are often interested to know if they should be taking any supplements.   
Author Interviews, Columbia, COVID -19 Coronavirus, Pediatrics / 06.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58598" align="alignleft" width="200"]Dani Dumitriu, MD, PhD Assistant Professor of Pediatrics (in Psychiatry) The Sackler Institute for Developmental Psychobiology Columbia University, New York Dr. Dumitriu[/caption] Dani Dumitriu, MD, PhD Assistant Professor of Pediatrics (in Psychiatry) The Sackler Institute for Developmental Psychobiology Columbia University, New York MedicalResearch.com: What is the background for this study? What are the main findings?  Response: A lot of research has focused on the effects of COVID-19 in various vulnerable populations, such as elderly individuals, immunocompromised patients, and individuals with severe comorbidities. However, one vulnerable population that has remained relatively understudied are the infants exposed to maternal COVID-19 disease during pregnancy. While early on in the pandemic we and other groups showed reassuring data on low risk of vertical transmission, meaning the passing of the virus from mother-to-infant is rare, this does not necessarily mean that these infants wouldn't experience long-term consequences related to the maternal infection through other means. We know from other viral illness that maternal illness, most commonly through the activation of her immune system, can lead to a cascade of events that affect fetal development. This is why a large number of physicians and researchers at Columbia University spearheaded the COVID-19 Mother Baby Outcomes (COMBO) Initiative -- to look at potential long-term health effects on both infants and mothers.
Author Interviews, NEJM, OBGYNE / 05.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58612" align="alignleft" width="150"]Laura Schummers, ScD, (she/her/hers) Postdoctoral Fellow, Contraception and Abortion Research Team  CIHR Patient-Oriented Research Leadership Fellow Post-doctoral Trainee, ICES McMaster UBC - Department of Family Practice | Women's Health Research Institute Dr. Schummers[/caption] Laura Schummers, ScD (she/her/hers) Postdoctoral Fellow, Contraception and Abortion Research Team CIHR Patient-Oriented Research Leadership Fellow Post-doctoral Trainee, ICES McMaster UBC - Department of Family Practice | Women's Health Research Institute MedicalResearch.com: What is the background for this study? Response: Canada was the first country in the world to remove all supplemental restrictions on the dispensing and administration of mifepristone, making the drug available as a normal prescription. This meant that the abortion pill could be prescribed by any doctor or nurse practitioner, dispensed by any pharmacist, and taken by patients when, where and if they choose.